Retatrutide
An investigational triple agonist (GLP-1, GIP, and glucagon receptors) that posted ~24% average loss in phase 2 trials.
Retatrutide is Eli Lilly's next swing after tirzepatide: a single molecule activating three receptors — GLP-1 and GIP, like tirzepatide, plus the glucagon receptor, which raises energy expenditure. In its published phase 2 trial, the highest dose averaged roughly 24% body-weight loss at 48 weeks, before the curve had plateaued.
As of this writing it remains investigational — phase 3 trials ongoing, no FDA approval, no legitimate way to be prescribed it outside a study. Any website selling "retatrutide" today is selling an unapproved research chemical. Its relevance for patients now is as a preview: the ceiling of medical weight loss keeps rising, and today's choice between semaglutide and tirzepatide won't be the last word.
This glossary entry is general information, not medical advice, and is written to be consistent with FDA prescribing information and primary trial publications as of its last review. Always consult a licensed healthcare provider for personal medical decisions.
Questions about Retatrutide? Ask a doctor free.
A licensed doctor can apply this to your health history in a free telehealth consultation — booking takes about two minutes, with programs from $149/month. You're only charged after approval.
Book an Appointment